Get access

Refractory pyoderma gangrenosum treated with infliximab in an infant


  • Conflict of interest: the authors declare that they have no conflicts of interest.


We report the case of an 11-month-old boy with severe recalcitrant pyoderma gangrenosum refractory to prednisone, dapsone and ciclosporin. Treatment with infliximab was well tolerated, and resulted in an excellent clinical response that has been sustained for 15 months. The characteristics of this condition in children and the use of infliximab in infants are both reviewed.

Get access to the full text of this article